---
layout: default
title: Aluminum Oxide Arctium Lappa Root Arsenic Trioxide
parent: 僅模型預測 (L5)
nav_order: 273
evidence_level: L5
indication_count: 0
---

# Aluminum Oxide Arctium Lappa Root Arsenic Trioxide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Preparation (26-Ingredient Homeopathic Formula): Unable to Evaluate — Insufficient Data for Drug Repurposing Assessment

## One-Sentence Summary

This submission contains a 26-ingredient preparation comprising heavy metals, herbal extracts, and mineral compounds characteristic of a complex homeopathic formula (including Mercurius solubilis, Nux vomica, Berberis vulgaris, and Arsenicum trioxide).
No original approved indication, no TxGNN predicted indication, and no registered market authorization in Taiwan were found.
With zero supporting evidence across all data dimensions, a meaningful repurposing evaluation cannot be completed at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available — no approved indication on record |
| Predicted New Indication | Not available — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only) — in this case, not even L5; no prediction was generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction was generated for this candidate. The system returned an empty `predicted_indications` array, which means the knowledge graph could not establish a statistically significant drug–disease association for any of the 26 listed ingredients as a combined entity.

This outcome is consistent with the nature of the submission: the compound's active ingredient list spans heavy metals (arsenic trioxide, lead, cadmium, beryllium, mercury as Mercurius solubilis), essential minerals (copper, iodine, selenium, sodium chloride), and botanical extracts (garlic, burdock root, barberry, oat, goldenrod, pokeweed, nux vomica). This profile is consistent with a complex homeopathic preparation in which each ingredient is typically present at extreme dilution, making pharmacological mechanism inference extremely difficult at the composite level.

No mechanism of action data is available. Without an identifiable MOA or approved indication, it is not possible to reason from first principles about potential repurposing targets.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

This drug has no US NDA or market authorization on record. No license table can be generated.

---

## Safety Considerations

> Please refer to the package insert for safety information.

> **Note for reviewers:** Several individual components in this preparation carry significant standalone toxicity concerns. Arsenic trioxide is a known carcinogen and requires strict monitoring even at therapeutic doses (as used in acute promyelocytic leukemia). Beryllium, cadmium, and lead are classified as hazardous heavy metals. Strychnos nux-vomica contains strychnine. Phytolacca americana (pokeweed) is toxic at non-homeopathic doses. If this preparation is being evaluated at pharmacological (non-homeopathic) concentrations, a full component-by-component toxicology review is mandatory before any further development step.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No TxGNN prediction was generated, no approved indication exists, and no regulatory authorization was found in any jurisdiction. The submission lacks the foundational data required to proceed with a drug repurposing evaluation.

**To proceed, the following is needed:**

- Clarify the identity and intended use of this preparation: Is this a homeopathic product at ultra-dilute concentrations, or a multi-component pharmacological formulation?
- If homeopathic: TxGNN-based repurposing is not the appropriate evaluation framework; homeopathic products should be assessed under a separate methodology
- If pharmacological: Provide per-ingredient concentrations, a unified MOA statement, and at minimum one registered indication or historical use record
- Obtain safety data (package insert, SDS sheets) for each of the 26 components individually
- Resolve data gaps DG001 (regulatory warnings/contraindications) and DG002 (MOA) before re-submitting to the TxGNN pipeline
- Confirm whether any single ingredient in the list — particularly arsenic trioxide — is the intended active entity, in which case a monotherapy Evidence Pack for that ingredient would be more appropriate
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

